Randomised controlled trial of lymphoblastoid interferon for chronic active hepatitis B

J Hepatol. 1986:3 Suppl 2:S225-7. doi: 10.1016/s0168-8278(86)80124-6.

Abstract

Thirty male patients (28 homosexual or bisexual) with biopsy proven chronic active hepatitis B were randomised to receive lymphoblastoid interferon (Wellferon) or no treatment. All patients were HBeAg-positive and had continuing viral replication. Interferon was given as a single daily i.m. injection for 28 days at a starting dose of 2.5 megaunits/m2 increasing to a maximum of 7.5 megaunits/m2/day. Transient side-effects occurred in all patients. Hepatitis B viral replication was suppressed during interferon treatment in all patients but the effect was limited to the period of therapy. After 1 year there was no appreciable difference in viral markers between the two groups of patients and this treatment schedule appears less effective than the thrice weekly, 3-month regimes reported from other centres.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Clinical Trials as Topic
  • Hepatitis B / therapy*
  • Hepatitis B virus / physiology
  • Hepatitis, Chronic / therapy*
  • Humans
  • Interferon Type I / therapeutic use*
  • Male
  • Random Allocation
  • Recombinant Proteins / therapeutic use*
  • Virus Replication

Substances

  • Interferon Type I
  • Recombinant Proteins